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ORIGINAL ARTICLE
Radiographic Progression of Patients With
Psoriatic Arthritis Who Achieve Minimal Disease
Activity in Response to Golimumab Therapy:
Results Through 5 Years of a Randomized,
Placebo-Controlled Study
ARTHUR KAVANAUGH,1 DESIREE VAN DER HEIJDE,2 ANNA BEUTLER,3 DAFNA GLADMAN,4
PHILIP MEASE,5 GERALD G. KRUEGER,6 IAIN B. MCINNES,7 PHILIP HELLIWELL,8
LAURA C. COATES,8 AND STEPHEN XU3
Objective. To evaluate long-term outcomes in psoriatic arthritis (PsA) patients who achieved or did not achieve mini-
mal disease activity (MDA) through 5 years of golimumab treatment in the GO-REVEAL trial.
Methods. The GO-REVEAL trial was a phase III, randomized, double-blind trial with placebo-control through week
24 followed by an open-label extension of golimumab 50/100 mg treatment up to 5 years. In these post-hoc analyses,
MDA was defined by the presence of ‡5 of 7 PsA outcome measures (£1 swollen joint, £1 tender joint, Psoriasis Area
and Severity Index [PASI] £1, patient pain score £15, patient global disease activity score £20 [range 0–100], Health
Assessment Questionnaire disability index [HAQ DI] £0.5, and £1 tender enthesis point).
Results. Treatment with golimumab yielded significantly higher MDA response rates versus patients randomized to
placebo at week 14 (23.5% versus 1.0%; P < 0.0001), week 24 (28.1% versus 7.7%; P < 0.0001), and week 52 (42.4%
versus 30.2%; P50.037). MDA was achieved at least once by ~50% of golimumab-treated patients overall. Irrespective
of treatment randomization, achievement of MDA at ‡3 and ‡4 consecutive visits was associated with significantly
less radiographic progression and more improvement in MDA components allowing specific assessment of physical
function (HAQ DI) and overall disease activity (patient global assessment of disease activity) at week 256 versus
patients not achieving MDA. Logistic regression analyses indicated that a 1-unit higher baseline HAQ DI score yielded
a significantly lower likelihood of achieving MDA at ‡3 (odds ratio 0.514 [95% confidence interval 0.321–0.824];
P5 0.006) and ‡4 (odds ratio 0.480 [95% confidence interval 0.290–0.795]; P50.004) consecutive visits.
Conclusion. Among golimumab-treated PsA patients, better long-term functional improvement, patient global assess-
ment, and radiographic outcomes were observed when patients achieved persistent MDA.
INTRODUCTION
With the advent of biologic agent therapy and the advance-
ment of treat-to-target recommendations for the manage-
ment of psoriatic arthritis (PsA), goals of therapy have
become more aggressive, with minimal disease activity
(MDA) being a feasible objective target (1–3). As defined by
the Outcome Measures in Rheumatology Clinical Trials
(OMERACT) group, MDA is “that state of disease activity
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deemed a useful target of treatment by both the patient and
physician, given current treatment possibilities and limi-
tations,” and encompasses both remission and low disease
activity (4). The PsA MDA criteria, a composite of 7 tools
used to assess disease activity, have been preliminarily val-
idated in both observational and interventional trial
cohorts (5,6).
In PsA, achievement of MDA earlier in the disease
course could potentially obviate the development of struc-
tural damage. As such, we evaluated long-term radio-
graphic progression and physical function in patients who
either achieved or did not achieve MDA through 5 years
of participation in the randomized, placebo-controlled,
GO-REVEAL study of golimumab in PsA patients (7–10).
PATIENTS AND METHODS
The GO-REVEAL trial was conducted according to guide-
lines set forth by the Declaration of Helsinki and Internation-
al Conference on Harmonization good clinical practices.
Specifically, the institutional review board or ethics commit-
tee at each study site approved the protocol, and all patients
provided written informed consent prior to the start of any
study-related procedures. Details of the GO-REVEAL patient
eligibility criteria and trial design have been previously pub-
lished (7–10). Despite treatment with disease-modifying
antirheumatic or nonsteroidal antiinflammatory drugs,
patients had active PsA, defined by the presence of at least 3
swollen and 3 tender joints, and the presence of plaque pso-
riasis with a qualifying lesion at least 2 cm in diameter.
The GO-REVEAL trial was a phase III, randomized,
double-blind trial with placebo-control through week 24
followed by an open-label extension lasting up to 5 years.
A total of 405 patients were randomized (1:1.3:1.3) to
receive blinded subcutaneous injections of placebo, goli-
mumab 50 mg, or golimumab 100 mg every 4 weeks. Ran-
domization was stratified by methotrexate (MTX) use
reported at baseline. Janssen Biotech supplied golimumab
and placebo as sterile liquids for subcutaneous injection.
At week 16, patients with ,10% improvement from base-
line in their swollen and tender joint counts entered early
escape, with dose escalation from placebo to golimumab
50 mg or from golimumab 50 mg to golimumab 100 mg.
Patients randomized to the golimumab 100 mg group had no
change in treatment based on week-16 response. Beginning
at week 24, all patients still receiving placebo crossed over
to golimumab 50 mg. Thus, all patients received blinded
golimumab 50 mg or 100 mg every 4 weeks between the
week 24 and week 52 database locks. Following the week 52
database lock, patients received open-label subcutaneous
golimumab (50 or 100 mg) injections every 4 weeks, and
patients receiving golimumab 50 mg or 100 mg could
increase or decrease the dose to 100 mg or 50 mg, respective-
ly, at the investigator’s discretion.
For the purpose of these post-hoc analyses, and as vali-
dated by Coates and Helliwell (5), MDA was defined as the
presence of at least 5 of the following 7 PsA outcome mea-
sures: swollen joint count #1 of 66 evaluated; tender joint
count#1 of 68 evaluated; Psoriasis Area and Severity Index
(PASI) #1 (range 0–72)(11); patient pain visual analog scale
(VAS) score #15 (range 0–100); patient global assessment of
disease activity VAS score of #20 (range 0–100); Health
Assessment Questionnaire disability index (HAQ DI) score
#0.5 (range 0–3)(12,13); and tender enthesis points#1.
These post-hoc analyses of the GO-REVEAL trial uti-
lized observed data from randomized patients with non-
missing MDA and/or radiographic data at weeks 14, 24,
52, 104, 148, 196, and 256, time points at which data were
available to analyze the MDA status. Analyses of variance
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 Patients with a 1-unit higher baseline Health Assess-
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nificantly lower likelihood of achieving MDA at $3
and$4 consecutive study visits.
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based on van der Waerden normalized scores were used for
1) treatment comparisons of MDA achievement; 2) compar-
isons of MDA achievement categories (never, $3 consecu-
tive time points, $4 consecutive time points) by
randomized treatment group and also by changes from
baseline to week 256 in the PsA-modified Sharp/van der
Heijde score (SHS) (14,15), HAQ DI score, PASI score
(among patients with$3% of body surface area with psori-
asis involvement at baseline), and patient global assess-
ment of disease activity; and 3) comparisons of MDA
achievement categories (never, $3 consecutive time
points, $4 consecutive time points) by MTX use at base-
line (yes/no). The endpoints of MDA achievement at $3
and$4 consecutive time points (in this case representing a
minimum of at least 38 and 90 weeks, respectively, with
minimal disease) were chosen to provide a reasonable
number of patients available for analysis per treatment
group within the context of a clinically meaningful and
sustained timeframe. Logistic regression analyses were
conducted to assess the effect of baseline disease character-
istics on achievement of MDA at $3 and $4 consecutive
time points. Baseline characteristics assessed included
HAQ DI score, MTX use, Disease Activity Score in 28 joints
using the C-reactive protein level (DAS28-CRP) (16,17),
patient global assessment of disease activity, PsA duration,
tender joint count, swollen joint count, and CRP level.
RESULTS
Patient disposition and baseline characteristics. As
reported previously (10), 126 of 405 patients (31.1%) discon-
tinued study treatment through week 252, with the most
common reasons for study agent discontinuation being ad-
verse events and unsatisfactory therapeutic response. Base-
line disease characteristics, as well as the proportions of
Table 1. Achievement of minimal disease activity at each visit assessed over 5 years by ran-
domized treatment and by baseline methotrexate (MTX) use in randomized patients included
in post-hoc analyses*
PlacebofiGolimumab
50 mg/100 mg†
Golimumab
50 mg/100 mg‡
MTX use
at baseline
No MTX use
at baseline
No. patients with
available data
106 289 194 201
Week 14 1/104 (1.0) 67/285 (23.5) 34/192 (17.7) 34/197 (17.3)
P , 0.0001 0.91
Week 24 8/104 (7.7) 80/285 (28.1) 40/192 (20.8) 48/197 (24.4)
P , 0.0001 0.41
Week 52 29/96 (30.2) 111/262 (42.4) 70/183 (38.3) 70/175 (40.0)
P 0.037 0.73
Week 104 32/87 (36.8) 107/250 (42.8) 69/177 (39.0) 70/160 (43.8)
P 0.33 0.37
Week 148 41/84 (48.8) 122/236 (51.7) 79/167 (47.3) 84/153 (54.9)
P 0.65 0.17
Week 196 37/82 (45.1) 106/222 (47.7) 74/161 (46.0) 69/143 (48.3)
P 0.68 0.69
Week 256 34/77 (44.2) 106/205 (51.7) 70/150 (46.7) 70/132 (53.0)
P 0.26 0.29
* Values are the numerator/denominator (%) of patients.
† Group includes patients randomized to placebo who early escaped/crossed over at week 16/24 to receive
golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week-52 database
lock. All patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock.
‡ Group includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or dose
escalated after the week-52 database lock to receive golimumab 100 mg and also includes patients randomized
to receive golimumab 100 mg. All patients could decrease the golimumab dose from 100 to 50 mg after the
week-52 database lock.
Figure 1. Proportions of patients who achieved minimal disease
activity by randomized treatment and visit over 5 years. The place-
bo!golimumab 50 mg/100 mg group includes patients randomized
to placebo who early escaped/crossed over at week 16/24 to receive
golimumab 50 mg, with the possibility to increase golimumab from
50 to 100 mg after the week-52 database lock. All patients could
decrease the golimumab dose from 100 to 50 mg after the week-52
database lock. The golimumab 50 mg/100 mg group includes patients
randomized to receive golimumab 50 mg who early escaped at week
16 or dose escalated after the week-52 database lock to receive goli-
mumab 100 mg and also includes patients randomized to receive
golimumab 100 mg. All patients could decrease the golimumab dose
from 100 to 50 mg after the week-52 database lock. EE5 early escape;
†5P< 0.0001 vs. placebo; ‡5P< 0.05 vs. placebo.
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patients reporting MTX use at baseline, were generally con-
sistent among randomized treatment groups (see Supplemen-
tary Table 1 available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22576/
abstract) and were generally consistent between patients who
continued and discontinued study agent (data not shown).
Table 2. Achievement of minimal disease activity (MDA) over 5 years in randomized
patients included in post-hoc analyses*
Placebofigolimumab
50 mg/100 mg†
Golimumab
50mg/100 mg‡ P
No. patients with available data 106 289
Achievement of MDA
Never 52 (49.1) 122 (42.2) 0.22
$1 consecutive time point 54 (50.9) 167 (57.8) 0.22
$2 consecutive time points 43 (40.6) 129 (44.6) 0.47
$3 consecutive time points 30 (28.3) 104 (36.0) 0.15
$4 consecutive time points 23 (21.7) 84 (29.1) 0.14
$5 consecutive time points 13 (12.3) 72 (24.9) 0.007
$6 consecutive time points 3 (2.8) 48 (16.6) 0.000
$7 consecutive time points 0 (0.0) 33 (11.4) 0.000
* Values are the number (%) of patients unless indicated otherwise.
† Group includes patients randomized to placebo who early escaped/crossed over at week 16/24 to
receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the
week-52 database lock. All patients could decrease the golimumab dose from 100 to 50 mg after the
week-52 database lock.
‡ Group includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or
dose escalated after the week-52 database lock to receive golimumab 100 mg and also includes
patients randomized to receive golimumab 100 mg. All patients could decrease the golimumab dose
from 100 to 50 mg after the week-52 database lock.
Figure 2. Mean change in psoriatic arthritis–modified Sharp/van der Heijde score (SHS) from baseline to week 256 by randomized treat-
ment (A, B) and by baseline methotrexate (MTX) use (C, D). Decreases from baseline in SHS represent improvement. (See Supplementary
Table 1 available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22576/abstract for baseline
SHS values). The placebo!golimumab 50 mg/100 mg group includes patients randomized to placebo who early escaped/crossed over at
week 16/24 to receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week-52 database lock. All
patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock. The golimumab 50 mg/100 mg group
includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or dose escalated after the week-52 database lock
to receive golimumab 100 mg and also includes patients randomized to receive golimumab 100 mg. All patients could decrease the goli-
mumab dose from 100 to 50 mg after the week-52 database lock. MDA5minimal disease activity; *5P, 0.005 vs. never achieved MDA;
‡5 P, 0.05 vs. never achieved MDA; **5P< 0.01 vs. never achieved MDA; †5P< 0.0001 vs. never achieved MDA.
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Achievement of MDA. Seven patients randomized to pla-
cebo and 3 patients randomized to golimumab treatment
were excluded from the MDA analyses due to missing data.
Thus, 395 of the 405 randomized patients (97.5%) were
included in these analyses. As shown in Table 1, treatment
with golimumab was associated with significantly larger pro-
portions of patients who achieved MDA when compared
with those receiving placebo during the placebo-controlled
period at week 14 (23.5% versus 1.0%; P, 0.0001) and week
24 (28.1% versus 7.7%; P , 0.0001), as well as following
crossover to golimumab at week 52 (42.4% versus 30.2%;
P5 0.037). Baseline MTX use did not affect the achievement
of MDA (Table 1).
Through week 256, MDA was achieved at least once by
approximately 50% of golimumab-treated patients (Figure 1).
In addition, larger proportions of golimumab-randomized
patients compared with placebo-randomized patients
achieved MDA at $5 (24.9% versus 12.3%; P5 0.007), $6
(16.6% versus 2.8%; P5 0.000), and$7 (11.4% versus 0.0%;
P5 0.000) consecutive time points (Table 2).
Impact of MDA on patient outcomes through 5 years.
Irrespective of treatment randomization, achievement of
MDA at$3 and$4 consecutive time points was associated
with significantly less radiographic progression (Figure 2)
and significantly more improvement in components of the
MDA criteria that allow specific assessment of physical
function, i.e., HAQ DI (Figures 3A and B), and overall dis-
ease activity, i.e., patient global assessment of disease
activity (Figures 3C and D), at week 256 when compared
with patients who never achieved MDA. Consistent with
absolute change in SHS, when assessed by the proportions
of patients who achieved SHS change ,0 from baseline to
year 5, there was a trend toward less progression among
patients who achieved MDA at $3 (41 of 116, 35.3%) and
$4 (34 of 95, 35.8%) consecutive time points versus
patients who never achieved MDA (22 of 95, 23.2%;
P50.054 and P50.056, respectively). In addition, similar
patterns of more improvement/less progression in SHS
were observed for patients who achieved MDA based on 6
of 7 and all 7 of the MDA components, especially with
longer durations of treatment when adequate numbers of
patients could be included in the subset of patients who
achieved MDA (see Supplementary Table 2 available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22576/abstract).
Achievement of MDA at $3 and $4 consecutive time
points did not appear to affect changes in the skin symptoms
of PsA, assessed by the PASI score, at week 256 when evalu-
ated in patients with $3% of body surface area with psoria-
sis involvement at baseline (Figures 4A and B). Of note,
patients who achieved persistent MDA and who reported
MTX use at baseline demonstrated significantly less radio-
graphic progression (Figures 2C and D) and significantly less
Figure 3. Mean change in Health Assessment Questionnaire disability index (HAQ DI) (A, B) and patient global assessment of disease
activity (PtGA) (C, D) from baseline to week 256 by randomized treatment. Decreases from baseline in HAQ DI represent improve-
ment and increases in PtGA indicate worsening disease activity (See Supplementary Table 1 available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22576/abstract for baseline HAQ DI and PtGA values). The
placebo!golimumab 50 mg/100 mg group includes patients randomized to placebo who early escaped/crossed over at week 16/24
to receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week-52 database lock. All
patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock. The golimumab 50 mg/100 mg
group includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or dose escalated after the week-52
database lock to receive golimumab 100 mg and also includes patients randomized to receive golimumab 100 mg. All patients
could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock. MDA5minimal disease activity; *5P ,
0.005 vs. never achieved MDA; †5P < 0.0001 vs. never achieved MDA.
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improvement in PASI score (Figures 4C and D) at week 256
than patients with MDA not receiving MTX. Effects of MTX
use were not observed for changes in HAQ DI or patient glob-
al assessment of disease activity (data not shown).
Logistic regression analyses were conducted to assess
the effect of baseline disease characteristics (HAQ DI
score, MTX use, DAS28-CRP, patient global assessment of
disease activity, PsA duration, tender joint count, swollen
joint count, and CRP level) on achievement of MDA at $3
and $4 consecutive time points. Analysis results revealed
that patients with a 1-unit higher baseline HAQ DI score
had a significantly lower likelihood of achieving MDA at
$3 (odds ratio [OR] 0.514 [95% confidence interval (95%
CI) 0.321–0.824]; P5 0.006) and $4 (OR 0.480 [95% CI
0.290–0.795]; P50.004) consecutive time points.
DISCUSSION
The phase III, randomized, double-blind GO-REVEAL trial
of 405 PsA patients treated with golimumab for up to 5
years (7–10) provided an opportunity to retrospectively
assess the implications of achieving a treatment goal,
namely MDA, that is more rigorous than the typical objec-
tives of therapeutic studies in PsA. The composite PsA
MDA criteria have been preliminarily validated in both
observational and interventional trial cohorts (5,6). Also,
it was previously found that MDA might be predicted after
3 months of anti-tumor necrosis factor (TNF) therapy by
factors such as baseline age, CRP level, and function (as
assessed by the Bath Ankylosing Spondylitis Functional
Index) in a smaller cohort (n5 146) of PsA patients (18).
The implications of achieving MDA over a longer time
period have not been explored to date. Based on patient
data collected from the GO-REVEAL study, treatment with
golimumab resulted in achievement of MDA in approxi-
mately 50% of patients through 5 years. Importantly, better
long-term functional improvement, patient global assess-
ment of disease activity, and radiographic, although not
skin, outcomes were observed when patients achieved per-
sistent MDA. Radiographic benefit in patients with persis-
tent MDA was more pronounced in patients using MTX at
baseline. Results of regression analyses identified baseline
HAQ DI score to be a significant predictor of a patient’s
ability to achieve persistent MDA, whereby patients with a
1-unit higher baseline HAQ DI score had a significantly
lower likelihood of achieving MDA at$3 and$4 consecu-
tive study visits.
Among patients who received placebo through the initial
16 or 24 weeks of the GO-REVEAL study, a 4- to 6-month
delay in initiation of golimumab did not result in a penalty
of the investigated clinical outcomes (HAQ DI, patient glob-
al assessment of disease activity). However, a delay in
Figure 4. Mean change in Psoriasis Area and Severity Index (PASI) score from baseline to week 256 by randomized treatment (A, B)
and by baseline methotrexate (MTX) use (C, D). Decreases from baseline indicate improved activity (See Supplementary Table 1
available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22576/abstract for baseline
PASI values). The placebo!golimumab 50 mg/100 mg group includes patients randomized to placebo who early escaped/crossed
over at week 16/24 to receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week-52 data-
base lock. All patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock. The golimumab
50 mg/100 mg group includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or dose escalated after
the week-52 database lock to receive golimumab 100 mg and also includes patients randomized to receive golimumab 100 mg. All
patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock. MDA5minimal disease activity;
‡5 P, 0.05 vs. without MTX at baseline; **5P < 0.01 vs. without MTX at baseline.
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active treatment appeared to lead to approximately twice
the amount of radiographic progression by year 5, although
the overall amount of progression was still significantly lim-
ited in patients who started on placebo and switched to
golimumab. It also appeared that delaying the start of goli-
mumab may have affected long-term skin improvement,
although there is not much difference between MDA
achievers and nonachievers, suggesting that the effect of
TNF inhibitors on the skin might be more universal than
the effect on other domains of patient response.
The analyses reported herein have several limitations.
While some GO-REVEAL patients achieved MDA at $5,
$6, and$7 consecutive time points, the endpoints of MDA
achievement at $3 and $4 consecutive time points were
primarily employed in analyses. These endpoints were
selected to provide ample patients available for analysis per
treatment group within the context of a clinically meaning-
ful sustained timeframe, in this case representing at least 38
and 90 weeks, respectively, of minimal disease. In addition,
MDA is a composite response achieved by meeting 5 of 7
possible criteria, and we do not discern if any of the 7 crite-
ria are more important in achieving MDA than others. Also,
while the MDA is based on a possible total of 68 tender and
66 swollen joints, we utilized the DAS28-CRP as a baseline
variable in the regression analyses conducted, which could
potentially underestimate the amount of arthritis. However,
the DAS28 is more commonly employed in both clinical
and research settings, and actual baseline joint counts were
also incorporated into the regression model. Finally, approx-
imately 30% of all GO-REVEAL patients discontinued over
the course of the 5-year trial. The analyses reported herein,
however, utilize observed data and derive from up to 395 of
the 405 randomized patients. In conclusion, in patients with
active PsA, aiming for MDA as part of a treat-to-target strate-
gy may provide long-term radiographic and functional
benefit.
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